H D Showalter

发表

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

O. H. Chan, W. Denny, G. Rewcastle, 2000, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.

W. Denny, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

J. Smaill, W A Denny, J M Nelson, 2001, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.

W A Denny, G H Lu, R L Panek, 1998, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.

W. Denny, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.

D. W. Fry, H. D. Showalter, W. Elliott, 1994, Anti-cancer drug design.

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.